Recovery · Antimicrobial Peptide

LL-37 (Cathelicidin)

LL-37 is a 37-amino-acid antimicrobial peptide derived from the human cathelicidin protein. Studied for chronic Lyme, biofilm-associated infections, wound healing, and immune modulation.

Category: Recovery & Healing Last updated 2026-06-19

LL-37 (Cathelicidin) at a glance

LL-37 is a 37-amino-acid antimicrobial peptide derived from the human cathelicidin protein. Studied for chronic Lyme, biofilm-associated infections, wound healing, and immune modulation. Mechanism: Cathelicidin antimicrobial peptide. Typical route: Subcutaneous. FDA status: Not FDA-approved. Dispensed primarily by peptide compounding pharmacies for off-label use in chronic infection, autoimmune, and recovery protocols.

Drug classCathelicidin antimicrobial peptide

Half-life~24 hours

RouteSubcutaneous

Common dosing100-500 mcg/day

FDA statusNot approved

Available throughCompounding pharmacies

Mechanism of action

LL-37 disrupts bacterial cell membranes, neutralizes lipopolysaccharide, and modulates the human immune response by activating macrophages and supporting tissue repair. It has direct antimicrobial activity against gram-positive and gram-negative bacteria, fungi, and some viruses.

Dosing reference

Subcutaneous: 100-500 mcg once daily, often cycled 5 days on / 2 days off for 4-8 weeks. Higher doses are used in some clinical protocols for chronic infectious conditions.

Dosing information is provided for educational reference and is not medical advice. Patients must not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.

FDA status & regulatory framework

Not FDA-approved. Dispensed primarily by peptide compounding pharmacies for off-label use in chronic infection, autoimmune, and recovery protocols.

U.S. telehealth providers that work with LL-37 (Cathelicidin)

#1 of 4

Defy Medical

88/100v3.0 six-pillar rubric

Starting at $160/mo. Defy Medical is one of the providers covered in our editorial directory that dispenses or coordinates LL-37 (Cathelicidin).

Read review →

#2 of 4

Marek Health

85/100v3.0 six-pillar rubric

Starting at $180/mo. Marek Health is one of the providers covered in our editorial directory that dispenses or coordinates LL-37 (Cathelicidin).

Read review →

#3 of 4

Heally

70/100v3.0 six-pillar rubric

Starting at $110/mo. Heally is one of the providers covered in our editorial directory that dispenses or coordinates LL-37 (Cathelicidin).

Read review →

#4 of 4

PeterMD

71/100v3.0 six-pillar rubric

Starting at $125/mo. PeterMD is one of the providers covered in our editorial directory that dispenses or coordinates LL-37 (Cathelicidin).

Read review →

Related recovery peptides

Browse the full Recovery & Healing category →

Frequently asked questions about LL-37 (Cathelicidin)

What is LL-37 used for?

LL-37 is most often used by patients with chronic Lyme disease, biofilm-related infections, or persistent inflammation. The peptide is also studied for skin-condition recovery and immune support.

Are there side effects?

Common reported side effects include flu-like symptoms, injection-site reactions, and short-term fatigue. Patients with autoimmune conditions need to consult their physician given the peptide's immunomodulatory effects.

Lead Medical Researcher

Dr. Sam Saberian

Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.

Medical Reviewer

Alen A. Schwartz, MD

Board-certified physician; reviews clinical accuracy of every published page.

Edited by

Julliana Edwards

Editorial standards, factual accuracy, and corrections workflow.

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence point	Published data	What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1	Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.	Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1	Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.	Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status	FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.	Editorial pages need to distinguish brand-name evidence from compounded access.
State access	Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.	Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%

Tirzepatide 15 mg-20.9%

Semaglutide placebo-2.4%

Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing